Literature DB >> 17314721

Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania.

Teri Carlson1, Charles A Reynolds2, Rochelle Caplan2.   

Abstract

This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone. One child had been maintained on valproic acid for years and risperidone was added. In the second case, valproic acid was introduced to a child who had been treated with risperidone for years. In both cases, discontinuing the valproic acid resulted in normalization of ammonia levels and cessation of the manic behavior. This case report alerts physicians to the importance of obtaining serum ammonia levels in children treated with valproic acid and risperidone who present with manic behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314721     DOI: 10.1097/chi.0b013e31802ed8b2

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  6 in total

1.  Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.

Authors:  Neel Patel; Katherine B Landry; Rachel E Fargason; Badari Birur
Journal:  Psychopharmacol Bull       Date:  2017-01-26

2.  Valproic acid-induced abnormal behavior.

Authors:  Nanjangud Chandrashekar Nagalakshmi; Madhan Ramesh; Gurumurthy Parthasarathi; Anand Harugeri; Mary Sam Christy; Belur Seshachala Keshava
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

3.  Association between the blood concentrations of ammonia and carnitine/amino acid of schizophrenic patients treated with valproic acid.

Authors:  Masazumi Ando; Hideaki Amayasu; Takahiro Itai; Hisahiro Yoshida
Journal:  Biopsychosoc Med       Date:  2017-07-05

4.  A Case Series of Severe Hyperammonemia Encephalopathy Related to Valproate: Can Antipsychotics Increase the Risk?

Authors:  Effat Davoudi-Monfared; Mojan Radmehr; Padideh Ghaeli; Maryam Mousavi
Journal:  Iran J Psychiatry       Date:  2019-07

5.  Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.

Authors:  Yu-Lung Tseng; Chi-Ren Huang; Chih-Hsiang Lin; Yan-Ting Lu; Cheng-Hsien Lu; Nai-Ching Chen; Chiung-Chih Chang; Wen-Neng Chang; Yao-Chung Chuang
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889

6.  Valproate-Induced Hyperammonemic Encephalopathy.

Authors:  Faiza Farooq; Javeria Sahib Din; Ali M Khan; Syeda Naqvi; Shanila Shagufta; Abdul Mohit
Journal:  Cureus       Date:  2017-08-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.